> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Expands Pfizer Bleeding Drug Approval
- URL: https://www.fdaweb.com/fda-expands-pfizer-bleeding-drug-approval/
- Published: 2026-06-08T12:00:00.000Z
- Updated: 2026-09-14T13:40:40.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161273

FDA has approved an expanded indication for Pfizer's hemophilia treatment Hympavzi (marstacimab-hncq), allowing its use in additional patient populations that have historically faced limited treatment options, according to the company. The approval extends use of the once-weekly injectable therapy to patients aged 12 years and older with hemophilia A or B who have developed inhibitors to standard factor replacement therapies, as well as children ages 6 to 11 with hemophilia A or B regardless of inhibitor status.

The expanded label makes Hympavzi the first subcutaneous non-factor therapy approved for children aged 6 to 11 with hemophilia B, according to Pfizer.

The approval addresses a significant unmet need among patients who develop inhibitors — antibodies that neutralize traditional clotting factor replacement therapies, the company says. Such inhibitors develop in roughly 20% of people with hemophilia A and about 3% of those with hemophilia B, often leaving patients with fewer effective treatment options.

Hympavzi works differently from conventional factor replacement therapies. Rather than replacing missing clotting factors, the drug targets tissue factor pathway inhibitor, a naturally occurring anticoagulant, helping restore balance in the body's clotting process.

The drug is administered through a prefilled auto-injector pen and requires once-weekly subcutaneous dosing without routine treatment-related laboratory monitoring.